Market Research Report
HORA-PDE6B - Emerging Drug Insight and Market Forecast - 2030
|Published by||DelveInsight Business Research LLP||Product code||959712|
|Published||Content info||50 Pages
Delivery time: 1-2 business days
|HORA-PDE6B - Emerging Drug Insight and Market Forecast - 2030|
|Published: September 8, 2020||Content info: 50 Pages||
"HORA-PDE6B - Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Retinitis pigmentosa in 7 Major Markets. A detailed picture of the HORA-PDE6B in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
HORA-PDE6B is a recombinant adeno-associated viral (rAAV) vector developed for the treatment of retinitis pigmentosa due to a mutation in the PDE6B gene. This gene replacement therapy provides an unmutated copy of the human PDE6B gene to replace the defective gene, in order to induce the expression of a functional PDE6B protein in the rod outer segment. HORA-PDE6B is administered as a sterile suspension of viral particles, injected directly into the subretinal space. This triggers the expression of the transgene in the rods (where the PDE6B subunit is expressed) as well as in the cones.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of HORA-PDE6B in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of HORA-PDE6B covering trial interventions, trial conditions, trial status, start and completion dates.